Mevrometostat Clinical Trials (2026): 1 Studies for Cancer of the Prostate & Hormone Sensitive Prostate Cancer

Where to Participate: All Mevrometostat Trial Sites in the U.S. (97 sites across 19 states)

Every actively recruiting Mevrometostattrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Mevrometostat clinical trials at a glance: phase × recruitment status

Recruiting Mevrometostat clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Mevrometostat pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All Mevrometostat trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Mevrometostat clinical trials: frequently asked questions

How many Mevrometostat clinical trials are there?

1 Mevrometostat clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.

Are Mevrometostat clinical trials recruiting in 2026?

Yes — 1 Mevrometostat trial is actively recruiting in 2026, with 97 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Mevrometostat being studied for?

Mevrometostat is being studied for Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer. The trials are grouped by indication on this page.

What phase is Mevrometostat in?

Mevrometostat clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Mevrometostat clinical trials?

The lead sponsor across the most Mevrometostat trials is Pfizer. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Mevrometostatas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.